medrysone

Trade name: hms

Small moleculeapproved

Approved

Nov 28, 1969

Medrysone is a synthetic glucocorticoid used to to treat inflammatory eye diseases such as allergic conjunctivitis, vernal conjunctivitis, and episcleritis. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1960s

  1. Nov 28, 1969

    Allergan — Earliest FDA Approval

  2. Nov 28, 1969

    Allergan — NDA Secondary Org

  3. Nov 28, 1969

    Allergan — NDA Organization

Indications

Mechanism of action

Approval history

  • approvedNov 28, 1969

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]4(C)CCC(=O)C=C14
Mol. weight
344.4877 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Discontinued

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 11beta-hydroxy-6alpha-methylpregn-4-ene-3,20-dione
  • 11beta-hydroxy-6alpha-methylpregn-4-ene-3,20-dione
  • 11-hydroxy-6-methylprogesterone
  • hms
  • hms
  • hms
  • hms liquifilm
  • hms suspension
  • hydroxymesterone
  • hydroxymesterone
  • hydroxymesterone
  • medrifar
  • medrocort
  • medrysone
  • medrysone
  • medrysone
  • medrysone
  • medrysone
  • medrysone
  • medrysone
  • medrysone
  • medrysone
  • medrysone
  • medrysone
  • u-8471
  • u-8471

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
AllerganFor profitNDA2Nov 28, 1969
AllerganFor profitNDANov 28, 1969